Proteome Sciences plc LON:PRM that Randox Laboratories Ltd presented the first results from a prospective trial using its Rapid Stroke Array at the EuroMedLab 2017 meeting in Athens earlier this month. This is a novel diagnostic test designed to improve the clinical management of stroke and is based on multiple biomarkers some of which have been licensed from Proteome Sciences and developed in association with the Biomedical Proteomics Research Group at the University of Geneva.
In a study of 192 individuals, led by Dr. Konstantinos Makris of KAT General Hospital, Athens, Greece, the Randox Rapid Stroke Array showed excellent performance in identifying stroke from mimic conditions and healthy controls, and in differentiating between ischaemic and haemorrhagic strokes.
With the presentation of these data, Randox and Proteome Sciences have agreed that a pre-established milestone for the delivery of a stroke array for research purposes has now been achieved and an associated payment of GBP100,000 will be made by Randox according to the contractual terms initially agreed in April 2012.
Commenting on the presentation, Dr Ian Pike, Chief Scientific Officer at Proteome Sciences LON:PRM, said: “The results from the first trial of the Randox Rapid Stroke Array are very encouraging and have confirmed the potential of biomarkers to provide clinicians with a clearer diagnosis and to improve patient management.”
John Lamont, Chief Scientist at Randox, said: “We are extremely pleased with the outcome of this study and look forward to the completion of a prospective registration trial which is currently being planned.”
